Xenetic Biosciences is a biotechnology business based in the US. Xenetic Biosciences shares (XBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.37 – a decrease of 8.17% over the previous week. Xenetic Biosciences employs 4 staff and has a trailing 12-month revenue of around $2.5 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – XBIO.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Xenetic Biosciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Xenetic Biosciences stock price (NASDAQ: XBIO)
Use our graph to track the performance of XBIO stocks over time.
Is it a good time to buy Xenetic Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Xenetic Biosciences price performance over time
Historical closes compared with the close of $3.37 from 2025-03-21
1 week (2025-03-14)
-3.71%
1 month (2025-02-24)
-15.54%
3 months (2024-12-24)
-18.80%
6 months (2024-09-24)
-10.85%
1 year (2024-03-22)
-12.69%
2 years (2023-03-23)
-19.76%
3 years (2022-03-23)
11
5 years (2020-03-23)
5.4
Xenetic Biosciences financials
Revenue TTM
$2.5 million
Gross profit TTM
$2.5 million
Return on assets TTM
-27.25%
Return on equity TTM
-45.48%
Profit margin
-161.58%
Book value
$4.56
Market Capitalization
$5.7 million
TTM: trailing 12 months
Xenetic Biosciences share dividends
We're not expecting Xenetic Biosciences to pay a dividend over the next 12 months.
Have Xenetic Biosciences's shares ever split?
Xenetic Biosciences's shares were
split on a 1:10 basis on 14 May 2023
. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xenetic Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Xenetic Biosciences shares which in turn could have impacted Xenetic Biosciences's share price.
Xenetic Biosciences share price volatility
Over the last 12 months, Xenetic Biosciences's shares have ranged in value from as little as $2.78 up to $5.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenetic Biosciences's is 2.181. This would suggest that Xenetic Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Xenetic Biosciences overview
Xenetic Biosciences, Inc. , a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies.
Frequently asked questions
What percentage of Xenetic Biosciences is owned by insiders or institutions? Currently 19.055% of Xenetic Biosciences shares are held by insiders and 6.436% by institutions.How many people work for Xenetic Biosciences? Latest data suggests 4 work at Xenetic Biosciences.When does the fiscal year end for Xenetic Biosciences? Xenetic Biosciences's fiscal year ends in December.Where is Xenetic Biosciences based? Xenetic Biosciences's address is: 945 Concord Street, Framingham, MA, United States, 01701What is Xenetic Biosciences's ISIN number? Xenetic Biosciences's international securities identification number is: US9840155033What is Xenetic Biosciences's CUSIP number? Xenetic Biosciences's Committee on Uniform Securities Identification Procedures number is: 984015107
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
